CY1105337T1 - Πρωτοτυπες διυδροπτepιδινονες, μεθοδος για την παραγωγη τους και η χρηση τους ως φαρμακευτικα μεσα - Google Patents

Πρωτοτυπες διυδροπτepιδινονες, μεθοδος για την παραγωγη τους και η χρηση τους ως φαρμακευτικα μεσα

Info

Publication number
CY1105337T1
CY1105337T1 CY20061101285T CY061101285T CY1105337T1 CY 1105337 T1 CY1105337 T1 CY 1105337T1 CY 20061101285 T CY20061101285 T CY 20061101285T CY 061101285 T CY061101285 T CY 061101285T CY 1105337 T1 CY1105337 T1 CY 1105337T1
Authority
CY
Cyprus
Prior art keywords
prototype
production
pharmaceutical agents
dihydroptepidinones
dihydropteridinones
Prior art date
Application number
CY20061101285T
Other languages
Greek (el)
English (en)
Inventor
Matthias Hoffmann
Matthias Grauert
Steffen Breitfelder
Christian Eickmeier
Gerald Pohl
Thorsten Lehmann-Lintz
Norbert Redemann
Gisela Schnapp
Martin Steegmaier
Eckhart Bauer
Jens Jürgen QUANT
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of CY1105337T1 publication Critical patent/CY1105337T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20061101285T 2001-09-04 2006-09-08 Πρωτοτυπες διυδροπτepιδινονες, μεθοδος για την παραγωγη τους και η χρηση τους ως φαρμακευτικα μεσα CY1105337T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10143272 2001-09-04
PCT/EP2002/009728 WO2003020722A1 (de) 2001-09-04 2002-08-30 Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
CY1105337T1 true CY1105337T1 (el) 2010-03-03

Family

ID=7697637

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101285T CY1105337T1 (el) 2001-09-04 2006-09-08 Πρωτοτυπες διυδροπτepιδινονες, μεθοδος για την παραγωγη τους και η χρηση τους ως φαρμακευτικα μεσα

Country Status (30)

Country Link
EP (1) EP1427730B1 (enExample)
JP (1) JP3876254B2 (enExample)
KR (1) KR100955589B1 (enExample)
CN (1) CN1551881A (enExample)
AR (1) AR036586A1 (enExample)
AT (1) ATE332898T1 (enExample)
AU (1) AU2002337047B2 (enExample)
BR (1) BRPI0212137A2 (enExample)
CA (1) CA2458699C (enExample)
CO (1) CO5560575A2 (enExample)
CY (1) CY1105337T1 (enExample)
DE (1) DE50207522D1 (enExample)
DK (1) DK1427730T3 (enExample)
EA (1) EA007062B1 (enExample)
EC (1) ECSP045003A (enExample)
ES (1) ES2268093T3 (enExample)
HR (1) HRP20040213A2 (enExample)
HU (1) HUP0401293A3 (enExample)
IL (2) IL160440A0 (enExample)
MX (1) MXPA04002067A (enExample)
MY (1) MY129751A (enExample)
NO (1) NO328804B1 (enExample)
NZ (1) NZ531928A (enExample)
PL (1) PL369740A1 (enExample)
PT (1) PT1427730E (enExample)
RS (1) RS51012B (enExample)
UA (1) UA76512C2 (enExample)
UY (1) UY27427A1 (enExample)
WO (1) WO2003020722A1 (enExample)
ZA (1) ZA200401365B (enExample)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60037321T4 (de) 1999-08-04 2010-01-07 Icagen, Inc. Benzanilide als öffner des kaliumkanals
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
MXPA05009068A (es) * 2003-02-26 2005-10-19 Boehringer Ingelheim Pharma Dihidro-pteridinonas, metodo para la produccion y uso del mismo en la forma de farmacos.
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP2008510771A (ja) * 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
EP1915155A1 (en) * 2005-08-03 2008-04-30 Boehringer Ingelheim International GmbH Dihydropteridinones in the treatment of respiratory diseases
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
KR20080095902A (ko) 2006-02-14 2008-10-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 디하이드로디아제핀
WO2007135374A1 (en) * 2006-05-19 2007-11-29 Astrazeneca Ab Dihydropteridine compounds as anti proliferative agents
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
WO2008009909A1 (en) * 2006-07-17 2008-01-24 Astrazeneca Ab Pteridimones as modulators of polo-like kinase
WO2008040951A1 (en) * 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
MX2009004077A (es) 2006-10-19 2009-05-05 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
EP1953163A1 (en) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
PT2139892E (pt) * 2007-03-22 2011-11-21 Takeda Pharmaceutical Pirimidodiazepinas substituídas úteis como inibidores da plk1
WO2008157235A1 (en) * 2007-06-13 2008-12-24 University Of Virginia Patent Foundation Rsk inhibitors as anti-septicemia agents
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
EP2190849B1 (en) * 2007-08-15 2013-11-20 Vertex Pharmceuticals Incorporated 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
NZ584760A (en) 2007-09-25 2012-03-30 Takeda Pharmaceutical Polo-like kinase inhibitors
US8598172B2 (en) 2007-12-04 2013-12-03 Nerviano Medical Sciences S.R.L. Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
JP5593234B2 (ja) 2008-03-11 2014-09-17 ユニバーシティー ヘルス ネットワーク ニューロペプチドｙ５ｒ（ｎｐｙ５ｒ）アンタゴニストを使用して癌を治療する方法
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
GB0807452D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd PLK inhibitors
US8093043B2 (en) 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
EP2303889A1 (en) 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
EA026557B1 (ru) 2008-12-09 2017-04-28 Джилид Сайэнс, Инк. Промежуточные соединения для получения модуляторов толл-подобных рецепторов
CA2772253C (en) 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
AU2010299579A1 (en) * 2009-09-25 2012-05-03 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
NZ599342A (en) 2009-09-25 2014-04-30 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
JP2013508456A (ja) 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ， エルエルシー ヘテロアリール化合物の合成方法および精製方法
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
JP2013515734A (ja) 2009-12-23 2013-05-09 エラン ファーマシューティカルズ，インコーポレイテッド ポロ様キナーゼの阻害薬としてのプテリジノン
WO2011101369A1 (en) 2010-02-17 2011-08-25 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for production and use thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US9493466B2 (en) 2011-10-19 2016-11-15 Signal Pharmaceuticals, Llc Treatment of cancer with TOR kinase inhibitors
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
ES2694413T3 (es) 2011-12-02 2018-12-20 Signal Pharmaceuticals, Llc Composiciones farmacéuticas de 7-(6-(2-hidroxipropan-2-il)piridin-3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino [2,3-b]pirazin-2(1H)-ona, una forma sólida de la misma y métodos para su uso
EP2812001B1 (en) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9006226B2 (en) 2012-02-23 2015-04-14 Boehringer Ingelheim International Gmbh Dihydropteridinones I
US8865716B2 (en) 2012-02-23 2014-10-21 Boehringer Ingelheim International Gmbh Dihydropteridinones II
CA2864905A1 (en) 2012-02-24 2013-08-29 Signal Pharmaceuticals, Llc Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
HK1212207A1 (en) 2013-01-16 2016-06-10 西格诺药品有限公司 Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EP2958919B1 (en) * 2013-02-21 2019-05-22 Boehringer Ingelheim International GmbH Dihydropteridinones i
EP2958918B1 (en) * 2013-02-21 2016-12-07 Boehringer Ingelheim International GmbH Dihydropteridinones ii
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
HK1221174A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法
EA030808B1 (ru) 2013-04-17 2018-09-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ
WO2014172432A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MX364101B (es) 2013-04-17 2019-04-12 Signal Pharm Llc Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata.
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
CA3143529A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
EP3019493B1 (de) * 2013-07-09 2017-06-14 Bayer Pharma Aktiengesellschaft Modifizierte bet-proteininhibitorische dihydrochinoxalinone und dihydropyridopyrazinone
CA2918910A1 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
CN103664845B (zh) * 2013-12-27 2016-02-10 湖南欧亚生物有限公司 一种Plk激酶抑制剂药物中间体7-氨基-2,3-二氢苯并呋喃-4-甲酸的制备方法
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
KR20160115953A (ko) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
US9737535B2 (en) 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015193228A1 (de) * 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe
WO2015193229A1 (de) * 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
KR20170024120A (ko) 2014-07-14 2017-03-06 시그날 파마소티칼 엘엘씨 치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
JP2017526741A (ja) 2014-08-08 2017-09-14 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体およびその使用
AU2015318061B2 (en) 2014-09-16 2018-05-17 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
CN107074860B (zh) 2014-09-16 2022-07-15 吉利德科学公司 制备toll样受体调节剂的方法
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
HK1256419A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途
PE20181287A1 (es) 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
EP3728268A4 (en) * 2017-12-22 2021-07-28 Dana-Farber Cancer Institute, Inc. NEK INHIBITORS AND METHODS OF USE
ES2969982T3 (es) * 2018-04-24 2024-05-23 Vertex Pharma Compuestos de pteridinona y usos de los mismos
CN108610343A (zh) * 2018-06-12 2018-10-02 杨文思 一种用于治疗癌症的表皮生长因子受体抑制剂及其合成方法
EP3833353A4 (en) * 2018-08-10 2022-08-24 Yale University Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
CN111039944B (zh) 2018-10-12 2021-11-23 中国科学院合肥物质科学研究院 Mst1激酶抑制剂及其用途
CN113637017B (zh) * 2021-08-12 2024-03-26 中国药科大学 含二氢喋呤结构的化合物及其制备方法与用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2645152B1 (fr) * 1989-03-30 1991-05-31 Lipha 3h-pteridinones-4, procedes de preparation et medicaments les contenant
CA2029651C (en) * 1989-11-17 2000-06-06 David D. Davey Tricyclic pteridinones and a process for their preparation
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
WO2001019825A1 (en) * 1999-09-15 2001-03-22 Warner-Lambert Company Pteridinones as kinase inhibitors
WO2002076954A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases

Also Published As

Publication number Publication date
AR036586A1 (es) 2004-09-22
ES2268093T3 (es) 2007-03-16
EA007062B1 (ru) 2006-06-30
EA200400368A1 (ru) 2004-12-30
CN1551881A (zh) 2004-12-01
NO20040680D0 (no) 2004-02-16
NO20040680L (no) 2004-02-16
JP2005501904A (ja) 2005-01-20
HUP0401293A2 (hu) 2004-10-28
NZ531928A (en) 2005-10-28
YU27304A (sh) 2006-08-17
IL160440A (en) 2009-09-01
JP3876254B2 (ja) 2007-01-31
WO2003020722A1 (de) 2003-03-13
BRPI0212137A2 (pt) 2016-06-28
ATE332898T1 (de) 2006-08-15
KR100955589B1 (ko) 2010-04-30
MXPA04002067A (es) 2004-06-07
AU2002337047B2 (en) 2008-01-10
ECSP045003A (es) 2004-04-28
MY129751A (en) 2007-04-30
IL160440A0 (en) 2004-07-25
AU2002337047B8 (en) 2003-03-18
CA2458699A1 (en) 2003-03-13
CO5560575A2 (es) 2005-09-30
DE50207522D1 (de) 2006-08-24
HRP20040213A2 (en) 2005-02-28
PL369740A1 (en) 2005-05-02
CA2458699C (en) 2010-10-19
EP1427730A1 (de) 2004-06-16
UA76512C2 (en) 2006-08-15
NO328804B1 (no) 2010-05-18
PT1427730E (pt) 2006-11-30
UY27427A1 (es) 2003-03-31
HUP0401293A3 (en) 2008-03-28
DK1427730T3 (da) 2006-11-06
ZA200401365B (en) 2005-05-27
EP1427730B1 (de) 2006-07-12
RS51012B (sr) 2010-10-31
KR20040029465A (ko) 2004-04-06

Similar Documents

Publication Publication Date Title
CY1105337T1 (el) Πρωτοτυπες διυδροπτepιδινονες, μεθοδος για την παραγωγη τους και η χρηση τους ως φαρμακευτικα μεσα
CY1114564T1 (el) Μεθοδος για την παραγωγη διϋδροπτεριδινονων
CY1105994T1 (el) Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων
CY1113625T1 (el) Μεθοδος για την παραγωγη συμπυκνωμενων παραγωγων της πιπεραζιν-2-ονης καθως και ενδιαμεσα προϊοντα της μεθοδου
CY1106752T1 (el) Διϋδροπτεριδινονες, μεθοδος για την παραγωγη τους και χρηση τους ως φαρμακων
CY1112495T1 (el) Κυτταροτοξικοι παραγοντες που περιλαμβανουν νεα παραγωγα τομαϋμυκινης
CY1113105T1 (el) Παραγωγα ξανθινης, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα
CY1108471T1 (el) Μεθοδος για την παραγωγη εστερων σκοπινης
YU72002A (sh) Benzoilpirazoli i njihova primena u ulozi herbicida
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
CY1105386T1 (el) Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
CY1110399T1 (el) Ρυθμιστες της τετραϋδροπυρανυλο κυκλοπεντυλο τετραϋδροπυριδοπυριδινης για την ενεργοτητα των υποδοχεων των χημειοκινων
CY1106969T1 (el) Αναστολεις dpp-iv
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
HRP20080664A2 (hr) Supstituirani piridinski herbicidi
CY1108183T1 (el) Θειαζολυλο-διυδρο-ινδαζολια
CY1106391T1 (el) 2-υποκατεστημενες πυριμιδινες
EA200702002A1 (ru) Замещённые производные пиразолилоксифенила, применяемые в качестве гербицидов
ATE469892T1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
ECSP056111A (es) Derivados de 2-acilamino-4-feniltiazol, su preparación y aplicación en terapeutica
CY1107429T1 (el) Υποκατεστημενες ν-κυκλοεξυλιμιδαζολινονες με τροποποιητικη δραση επι της mch
CY1113911T1 (el) Παραγωγα sf5 ως αναστολεις par1, η παρασκευη τους και η χρηση τους ως φαρμακα
EA200600621A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
NO20052884L (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung